Exhibitors Search
Atomatrix Inc.
Booth no.
H50
|
Exhibition
|
|KOREA LIFE SCIENCE |
|---|---|
|
Country
|
| Korea, South |
|
Address
|
|7 Huseok-ro 462beon-gil, Chuncheon-si, Gangwon-do, Republic of Korea |
|
Tel
|
|+82-50-6808-2490 |
|
Exhibits
|
| CANDDIE: AI/MD-Based Drug Design Platform for GPCRs and Other Membrane Protein Targets |
|
Company Type
|
| Biotech Venture / Startup , etc(AI 기반 신약설계/CADD 기업) |
Exhibitor Information
CANDDIE™ is an AI/MD-based CADD platform for challenging membrane protein targets, including GPCRs. Using client-provided target structures, compound sets, and project-specific MoA and hit/lead criteria, the workflow combines structure modeling, compound screening, docking, MD simulation, and post-MD analysis. Outputs support candidate prioritization through binding-affinity estimation, dynamic binding-stability assessment, and, where relevant, post-binding signaling analysis. CANDDIE is currently used in B2B research projects and is being developed as a cloud-based SaaS platform.
Exhibit Description
CANDDIE™ is Atomatrix’s AI- and molecular dynamics (MD)-based drug design platform for challenging membrane-protein targets, including GPCRs. It integrates target modeling, virtual screening/docking, MD, and post-MD analysis into one workflow for drug discovery researchers and CADD experts. In the post-MD stage, BARon™ evaluates binding affinity and dynamic stability to support compound prioritization, while Allopiper™ analyzes ligand-induced allostery and signaling-related structural changes for mechanism-based differentiation. Together, they support efficient compound selection by considering both binding and mechanistic differences. CANDDIE is currently used in paid B2B projects with Korean pharma/biotech companies, with SaaS beta planned for Q4 2026 and commercial launch in Q1 2027.
Individual Exhibit/Technology Introduction (Detailed)
-
Product Name : CANDDIE™ AI/MD-Based Drug Design PlatformCANDDIE™ is an AI/MD-based CADD platform for challenging membrane protein targets, including GPCRs. Using client-provided target structures, compound sets, and project-specific MoA and hit/lead criteria, the workflow combines structure modeling, compound screening, docking, MD simulation, and post-MD analysis. Outputs support candidate prioritization through binding-affinity estimation, dynamic binding-stability assessment, and, where relevant, post-binding signaling analysis. CANDDIE is currently used in B2B research projects and is being developed as a cloud-based SaaS platform.
-
Product Name : BARon™ & Allopiper™ ? Core Post-MD Analysis Technologies within CANDDIE™BARon™ and Allopiper™ are core post-MD analysis technologies within CANDDIE. BARon™ uses MD simulation data to assess drug?target binding affinity and dynamic binding stability, supporting compound comparison and prioritization. Allopiper™ analyzes ligand-induced allosteric communication and structural changes related to signaling proteins, supporting evaluation of post-binding signaling characteristics in GPCR systems.
KYUNGYON EXHIBITION CORP.
